Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stocks Crossing The 13 Week Moving Average <$10.01 -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (9732)	9/11/2001 6:33:50 AM
From: tuck	Read Replies (1) \| Respond to of 13094

Sergio, Bernard asked me if I had anything to add to his diabetes list. Not much. ARDM (<$10.01) competes with INHL in pulmonary delivery of insulin. Ligand (<$10.01)/Lilly should be filing an IND any day now: Message 14516677 Also, Tularik has a preclinical compound, as do some others. CYGN is launching the GlucoWatch for monitoring blood sugar more often & less invasively than sticking yourself multiple times per day, and the recently munched MiniMed will compete in that area. Cheers, Tuck